IGF2BP3 binds to FBXO32 to activate the cyclic guanosine monophosphate-protein kinase G pathway, promoting gastric cancer progression

Table 1 The expression level of IGF2BP3 protein in two groups

Group	Cases	IGF2BP3 expression		Positive rate (%)	χ2 value	P value
		High	Low
Gastric cancer tissues	63	38	25	60	22.415	< 0.001c
Adjacent normal tissues	63	12	51	19

^cP < 0.001.

Table 2 The relationship between the expression of IGF2BP3 in gastric cancer tissue and the clinicopathological data of patients

Group	Cases	IGF2BP3 expression		χ2 value	P value
		High	Low
Gender
Male	48	33	15	2.404	0.121
Female	15	7	8
Age (years)
≤ 60	16	11	5	0.256	0.613
> 60	47	29	18
Tumor size (cm)
< 5	34	20	14	1.550	0.2131
≥ 5	27	20	7
Differentiation
Well	27	14	13	2.762	0.097
Poorly	36	26	10
Lauren classification
Intestinal type	33	18	15	3.873	0.049a,1
Diffuse type	28	22	6
Lymph node metastasis
Negative	18	5	13	13.867	< 0.001c
Positive	45	35	10
TNM staging
0	2	0	2	17.037	0.001b
I	4	0	4
II	17	9	8
III	30	21	9
IV	10	10	0
Invasion range
Tis	2	0	2	14.165	0.001b
T1	3	0	3
T2	8	5	3
T3	5	1	4
T4	45	34	11

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

¹Two cases of carcinoma in situ were excluded.

TNM: Tumor node metastasis.